Clinical Trial Update: A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of ponatinib with mini-hyper CVD chemotherapy and venetoclax in relapsed or refractory T-cell acute lymphoblastic leuk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Ponatinib (Iclusig) (ponatinib)
• Venetoclax (Venclyxto) (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Lymphoblastic Leukemia, Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING